A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC)

被引：0
|
作者：
Dizman, Nazli
Adra, Nabil
Vaishampayan, Ulka N.
Xiao, Lianchun
Yuan, Ying
Campbell, Matthew T.
Gao, Jianjun
Zurita, Amado J.
Jonasch, Eric
Tannir, Nizar M.
Shah, Amishi Yogesh
Msaouel, Pavlos
Hahn, Andrew Warren
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN USA
[3] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Div Canc Med, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4542
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of immune checkpoint inhibitors (ICI) in metastatic non-clear cell renal cell carcinoma (nccRCC): An institutional experience
    Schwartzman, William
    Elias, Roy
    Patel, Viral M.
    Bowman, Alex Isaac
    Chintalapati, Suneetha
    Kapur, Payal
    Hammers, Hans J.
    Brugarolas, James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [42] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
    Zhu, Jason
    Pabla, Sarabjot
    Labriola, Matthew
    Gupta, Rajan T.
    McCall, Shannon
    George, Daniel J.
    Dressman, Devin
    Glenn, Sean
    Nesline, Mary
    George, Saby
    Morrison, Carl
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [43] Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
    Simonaggio, Audrey
    Epaillard, Nicolas
    Pobel, Cedric
    Moreira, Marco
    Oudard, Stephane
    Vano, Yann-Alexandre
    CANCERS, 2021, 13 (02) : 1 - 22
  • [44] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
    Zhu, Jason
    Pabla, Sarabjot
    Labriola, Matthew
    Gupta, Rajan T.
    McCall, Shannon
    George, Daniel J.
    Dressman, Devin
    Glenn, Sean
    George, Saby
    Morrison, Carl
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] Immune checkpoint inhibitors (ICI) in clear cell renal cell carcinoma (ccRCC) following high-dose interleukin-2 (IL-2)
    Elias, Roy
    Bowman, Isaac Alexander
    Hammers, Hans J.
    Brugarolas, James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [46] Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Hudes, Gary R.
    Ginsberg, Michelle S.
    Baum, Michael S.
    Harmon, Charles S.
    Kim, Sindy T.
    Chen, Isan
    Redman, Bruce G.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (06): : 614 - 618
  • [47] Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial
    Fitzgerald, Kelly N.
    Lee, Chung-Han
    Voss, Martin H.
    Carlo, Maria I.
    Knezevic, Andrea
    Peralta, Laura
    Chen, Yingbei
    Lefkowitz, Robert A.
    Shah, Neil J.
    Owens, Colette N.
    Mchugh, Deaglan J.
    Aggen, David H.
    Laccetti, Andrew L.
    Kotecha, Ritesh R.
    Feldman, Darren R.
    Motzer, Robert J.
    EUROPEAN UROLOGY, 2024, 86 (02) : 90 - 94
  • [48] Efficacy and safety of cadonilimab plus lenvatinib in previously immunotherapy treated advanced/metastatic clear cell renal cell carcinoma (ccRCC): A multicenter, single-arm, phase II trial
    Huang, J.
    Zhao, J.
    Hu, X.
    Kong, W.
    Chen, Q.
    Zhang, J.
    Chen, Y.
    Guo, J.
    Xu, D.
    Xue, W.
    ANNALS OF ONCOLOGY, 2024, 35 : S1512 - S1512
  • [49] Comparative real-world effectiveness of PD-1/L1 inhibitor (PD-1i) plus cabozantinib (cabo) vs cabo after progression with prior immune checkpoint inhibitor (ICI) treatment (Rx) in metastatic clear cell renal cell carcinoma (mccRCC)
    Swami, U.
    Jo, Y. Jung
    Thomas, V. Mathew
    Gebrael, G.
    Li, H.
    Sayegh, N.
    Tripathi, N.
    Srivastava, A.
    Nordblad, B.
    Dal, E.
    Brundage, J.
    Campbell, P.
    Fortuna, G. Galarza
    Chehade, C. Hage
    Maughan, B. L.
    Agarwal, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S1021 - S1021
  • [50] Immune-related expression profiles and sunitinib response in metastatic clear cell renal cell carcinoma (ccRCC)
    Reig, Oscar
    Marin, Mercedes
    Jimenez, Natalia
    Pare, Laia
    Galvan, Patricia
    Mallofre, Carmen
    Prat, Aleix
    Mellado, Begona
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345